Chung Hyun Hoon, Kim Seok-Ki, Kim Tae Hyun, Lee Sun, Kang Keon Wook, Kim Joo-Young, Park Sang-Yoon
Research Institute and Hospital, National Cancer Center, 809 Madu-dong, Ilsan-gu, Goyang, Gyeonggi 411-769, Republic of Korea.
Gynecol Oncol. 2006 Oct;103(1):165-70. doi: 10.1016/j.ygyno.2006.02.016. Epub 2006 Mar 29.
To evaluate the ability of whole-body 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) scan to detect recurrent cervical cancer in women during follow-up after definitive treatment.
We retrospectively reviewed the whole-body FDG-PET scan of the women who had reached complete response after primary treatment for detection of recurrent cervical cancer between September 1, 2001 and October 31, 2004.
One hundred twenty-one consecutive patients were registered for the current study and seventy-six women were diagnosed as recurrence, twenty of which were asymptomatic. The FDG-PET scan detected 73 (96.1%) patients among 76 patients with recurrent disease and discriminated 38 (84.4%) patients among 45 patients without recurrence. The sensitivity, specificity and accuracy of the FDG-PET scan in assessment of recurrence among patients with cervical cancer were 96.1%, 84.4% and 91.7% respectively. Sixteen patients with no evidence of distant metastasis on FDG-PET scan received pelvic exenteration; complete response was achieved in 6 (37.5%) patients, and all are alive with no evidence of disease. The FDG-PET scan detected FDG-avid lesions in 17 (85.0%) of the 20 asymptomatic patients with recurrent disease, and 8 (40.0%) patients received therapy with curative intent; complete response was achieved in five (25.0%) patients and all are alive with no evidence of disease. Three-year overall survival of this study was 85.6%.
The whole-body FDG-PET scan is a sensitive post-therapy surveillance modality for detection of recurrent cervical cancer even in asymptomatic patients and aids in deciding treatment plans and, eventually, may have favorable impact on prognosis and survival.
评估全身2-[(18)F]-氟-2-脱氧-D-葡萄糖（FDG）正电子发射断层扫描（PET）在宫颈癌根治性治疗后随访期间检测复发癌的能力。
我们回顾性分析了2001年9月1日至2004年10月31日期间接受过原发治疗且达到完全缓解的女性的全身FDG-PET扫描结果，以检测复发性宫颈癌。
本研究共纳入121例连续患者，其中76例被诊断为复发，20例无症状。FDG-PET扫描在76例复发患者中检测出73例（96.1%），在45例未复发患者中鉴别出38例（84.4%）。FDG-PET扫描评估宫颈癌复发的敏感性、特异性和准确性分别为96.1%、84.4%和91.7%。16例FDG-PET扫描未显示远处转移证据的患者接受了盆腔脏器清除术；6例（37.5%）患者达到完全缓解，且均存活，无疾病证据。FDG-PET扫描在20例无症状复发患者中的17例（85.0%）检测到FDG摄取性病变，8例（40.0%）患者接受了根治性治疗；5例（25.0%）患者达到完全缓解，且均存活，无疾病证据。本研究的三年总生存率为85.6%。
全身FDG-PET扫描是一种敏感的治疗后监测方法，即使对于无症状患者也能检测出复发性宫颈癌，有助于制定治疗方案，并最终可能对预后和生存产生有利影响。
